Project Grant R44AI155116

The Department of Defense, through the Military Medical Research and Development program (CFDA 12.420), awarded a $1,857,470 Cooperative Agreement to The Geneva Foundation to develop a multiplex testing platform that can simultaneously detect and identify Plasmodium species infections. This platform will serve as both a diagnostic tool and an epidemiological surveillance tool. The project performance period is from June 1, 2024 to May 31, 2028. Under a $268,312 sub-award, Meso Scale...

This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), will support the development of a novel universal rapid test for HIV diagnosis. IGE Immunodiagnostics & Therapeutics, LLC, a minority-owned small business, will receive $294,948 to adapt their existing HIV ELISA test into a 5th generation antigen/antibody combination rapid test format. The goal is to create a simple, rapid,...

Federal Project Grant Award Summary L2 Diagnostics LLC received a $293,142 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded September 21, 2025, with completion targeted for August 31, 2027. The awardee will develop a rapid diagnostic test (RDT) in lateral flow assay (LFA) format to detect Babesia microti infection through antigen capture enzyme-linked immunosorbent assay...

This National Science Foundation (NSF) Small Business Innovation Research (SBIR) Phase I award to RT Microdx Inc. provides $274,362 to develop a novel molecular diagnostic platform for detecting respiratory diseases like strep throat. The platform aims to provide laboratory-quality accuracy for at-home use by non-healthcare professionals. Key technical objectives include optimizing the sensitivity of the platform's pH-sensitive polymer detection mechanism and ensuring robust performance at...

Federal Cooperative Agreement Summary Prompt Diagnostics, Inc. received a $1.25M Cooperative Agreement from the National Science Foundation (NSF) Technology, Innovation, and Partnerships (TIP) program (CFDA 47.084), awarded June 15, 2025, with completion targeted for May 31, 2027. The company is developing an automated, multiplexed point-of-care diagnostic platform for rapid detection and quantification of Treponema pallidum infections (syphilis). The solution integrates magnetic...

Federal Grant Award Summary Pace Diagnostics, Inc. received a $600,000 Project Grant award from the Centers for Disease Control and Prevention (CDC) Investigations and Technical Assistance program (CFDA 93.283) effective September 30, 2025, with a completion date of March 31, 2026. The award supports the development of an ultrasensitive urine tuberculosis antigen rapid detection test designed to improve the diagnosis of active tuberculosis. This innovation addresses a critical public health need...

The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $238,500 Project Grant under the Allergy and Infectious Diseases Research (CFDA 93.855) federal grant program to the University of California, San Diego (UCSD) to develop a novel electrochemical lateral flow assay (ELFA) for diagnosing tuberculosis (TB) from a single drop of blood. The objective is to create a highly sensitive and specific point-of-need TB detection test that can accurately distinguish active TB from...

This National Science Foundation (NSF) Partnerships for Innovation - Research Partnerships (PFI-RP) project grant, CFDA #47.084, provides $549,649 to the University of Rochester to advance the development of a novel membrane-based sensor technology for the rapid and specific detection of infectious pathogens in biofluids. The project aims to integrate the membrane sensor into a hand-operated microfluidic device with a colorimetric readout, and demonstrate the generalizability of the approach...

The National Science Foundation (NSF) awarded a $550,000 Project Grant under the NSF Technology, Innovation, and Partnerships (TIP) program to the University of California, Los Angeles (UCLA) to develop a rapid, multiplexed diagnostic tool for serological testing of tick-borne diseases (TBDs). This 2-year project seeks to improve blood-based detection of TBDs, including Lyme disease, Babesia, Anaplasma, and relapsing fever, through an innovative point-of-care (POC) serological assay. The goal is...

Federal Grant Award Summary L2 Diagnostics LLC received a $299,644 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded on September 23, 2025, with a completion date of August 31, 2027. The grant supports the development of a transmission-blocking vaccine (TBV) targeting mosquito metabolic pathways to interrupt malaria transmission. The company will refine its prototype TBV candidate...